U.S. Marine and Shipping Stock News

NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative?

In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome workflow and expanded Illumina Laboratory Services to support Florida State University’s new pediatric rare disease diagnostic lab with clinical sequencing and interpretation. Together, these moves pair higher‑resolution sequencing technology with real‑world clinical deployment, underscoring Illumina’s push to make advanced rare disease diagnostics more accessible and operationally efficient for hospitals and...
NasdaqCM:WULF
NasdaqCM:WULFSoftware

TeraWulf Recasts Bitcoin Roots Into Contracted AI And HPC Platform

TeraWulf (NasdaqCM:WULF) is shifting its core focus from bitcoin mining to large scale AI and high performance computing infrastructure. The company has executed over $12.8b in long term contracted revenue tied to this pivot. TeraWulf is planning multi gigawatt data center capacity expansions to support AI and HPC workloads. New partnerships include arrangements with Google backed ventures that feature strong credit enhancement. TeraWulf’s move into AI and HPC data center leasing comes at a...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Roku (ROKU) Valuation Check After Return To Profit And Nearly 100 Million Streaming Households Reached

Roku (ROKU) just followed up a stronger fourth quarter with a slot at Bernstein’s “What’s next in tech?” forum, giving investors fresh context on its earnings, platform reach, and position as a neutral streaming aggregator. See our latest analysis for Roku. Roku’s recent 16.2% 7 day share price return and 22.2% 1 year total shareholder return sit against a weaker year to date share price return of 9.8% decline, suggesting momentum has picked up again around its earnings and platform...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

Assessing Nuvation Bio (NUVB) Valuation After SIGMA Phase 3 Safusidenib Expansion And Rising Investor Interest

Nuvation Bio (NUVB) just finalized a protocol amendment that advances its global SIGMA safusidenib study into Phase 3, widening access for high risk IDH1 mutant astrocytoma patients and drawing additional investor attention to upcoming earnings. See our latest analysis for Nuvation Bio. The share price, now at US$5.84, has a 7 day share price return of 7% and a 30 day share price return of 11%, but a 90 day share price return of a 22% decline. The 1 year total shareholder return is over 3x...
NYSE:VZ
NYSE:VZTelecom

Verizon V2X Collaboration Tests 5G Edge As New Growth Platform

Verizon Communications (NYSE:VZ) is working with Aptiv PLC and Wind River on a scalable Vehicle-to-Everything (V2X) connected driving solution. The proof of concept uses Verizon’s 5G and edge compute infrastructure to share vehicle sensor data in near real time across different manufacturers. The collaboration was shown at MWC Barcelona and is built to support safety features such as automatic emergency braking through standardized APIs and existing vehicle hardware. For investors watching...
NasdaqGM:URGN
NasdaqGM:URGNBiotechs

UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives

UroGen Pharma FY 2025 results set the stage for growth versus losses debate UroGen Pharma (URGN) closed out FY 2025 with Q4 revenue of US$37.8 million and a basic EPS loss of US$0.54, alongside a trailing twelve month loss of US$3.19 per share on US$109.8 million of revenue. The company has seen quarterly revenue move from US$24.6 million in Q4 2024 to US$37.8 million in Q4 2025. Over the same period, basic EPS ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.54 in the latest...
NasdaqGS:KLAC
NasdaqGS:KLACSemiconductor

Assessing KLA (KLAC) Valuation After Strong Recent Share Price Momentum

Why KLA (KLAC) is on investors’ radar right now KLA (KLAC) has drawn fresh attention after its recent share move, with the stock last closing at US$1,534.95 and delivering a 7.5% return over the past month and 29% in the past 3 months. See our latest analysis for KLA. Beyond the recent move, KLA’s momentum has been building, with a 7 day share price return of 3.2%, a 30 day return of 7.5% and a 1 year total shareholder return of about 124%, pointing to strong recent enthusiasm for the...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Quantum Computing Inc Expands Quantum Platform With Foundry And Early Sales

Quantum Computing Inc. (NasdaqCM:QUBT) has completed its acquisition of Luminar Semiconductor and opened a major quantum chip foundry. The company has reported first commercial sales of its quantum cybersecurity solutions, including a contract with a major U.S. bank. Quantum Computing Inc. is collaborating with NASA under a subcontract and plans to expand its manufacturing capacity. Quantum Computing Inc. (NasdaqCM:QUBT), trading at $8.59, is shifting from a pure technology developer toward...
NasdaqGS:IBKR
NasdaqGS:IBKRCapital Markets

Interactive Brokers Growth, Stablecoin Funding And Valuation Risks In Focus

Interactive Brokers Group (NasdaqGS:IBKR) reports strong growth in client activity and trading volumes. The broker launches stablecoin funding for U.S. clients, allowing deposits in certain digital dollar tokens. The company highlights continued progress in brokerage technology and its inclusion in the S&P 500 Index. Interactive Brokers Group, trading at around $71.67, sits in a very different place than it did a few years ago, with a 1 year return of 43.0% and a 5 year return of 288.5%...
NasdaqCM:IMNM
NasdaqCM:IMNMBiotechs

How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors

Immunome, Inc. recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, updating investors on its oncology-focused pipeline and regulatory plans. A key highlight is the company’s push toward a New Drug Application for Varegacestat in desmoid tumors, alongside multiple upcoming solid tumor IND submissions and an FDA-cleared radioligand therapy trial. We’ll now examine how Immunome’s renewed oncology focus and advancing Varegacestat program might influence the company’s...
NYSE:UMH
NYSE:UMHResidential REITs

Why UMH (UMH) Is Down 6.2% After Mixed 2025 Earnings and Upbeat 2026 Guidance

In February 2026, UMH Properties, Inc. reported its fourth-quarter and full-year 2025 results, with quarterly revenue rising to US$66.97 million but quarterly net income slipping to US$4.64 million, while full-year revenue climbed to US$261.75 million and net income to US$26.5 million. Alongside these mixed quarterly figures, UMH outlined plans for continued portfolio expansion and issued upbeat 2026 guidance, highlighting expectations for higher normalized FFO and earnings per share...
NYSE:BG
NYSE:BGFood

Is It Time To Reconsider Bunge Global (BG) After The Viterra Merger Re-Rating?

If you are wondering whether Bunge Global’s current share price lines up with its underlying worth, this article walks through the key numbers that matter for valuation. The stock recently closed at US$120.61, after a 0.6% decline over 7 days, a 5.9% gain over 30 days, and returns of 30.2% year to date, 73.1% over 1 year, 34.3% over 3 years, and 75.8% over 5 years. Recent coverage has focused on Bunge Global’s role in global agribusiness and food supply chains and how that positioning may...
NasdaqGS:ASTS
NasdaqGS:ASTSTelecom

AST SpaceMobile Contract And Carrier Deals Reframe Commercial Potential

AST SpaceMobile (NasdaqGS:ASTS) has secured a major U.S. government contract with the Space Development Agency to provide direct to device tactical satellite communications. The company plans to use its BlueBird satellite constellation to support low latency defense communications under this new agreement. AST SpaceMobile has also announced new partnerships with Orange, Verizon, and stc Group as it moves toward commercial service. Recent satellite deployments and carrier agreements indicate...
NYSE:FDP
NYSE:FDPFood

Assessing Fresh Del Monte Produce (FDP) Valuation After Earnings Dividend And Buyback Update

Why Fresh Del Monte Produce (FDP) is back in focus Fresh Del Monte Produce (FDP) just reported fourth quarter and full year 2025 results, along with a fresh dividend declaration and an update on its completed share buyback. This gives investors several moving parts to assess at once. See our latest analysis for Fresh Del Monte Produce. The recent update on earnings, dividends and buybacks comes after a strong run in the share price, with a 16.84% 3 month share price return and a 47.18% 1 year...
NYSE:NEE
NYSE:NEEElectric Utilities

Assessing NextEra Energy (NEE) Valuation After A $2 Billion Composite Units Offering

NextEra Energy (NEE) has just completed a $2 billion composite units offering, combining future common stock purchase contracts with debentures, to fund energy and power projects and broader corporate needs, including debt repayment. See our latest analysis for NextEra Energy. At a share price of $92.71, NextEra Energy has seen a 30 day share price return of 5.47% and a 90 day share price return of 9.61%. Its 1 year total shareholder return of 33.29% and 5 year total shareholder return of...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit Anthropic AI Alliance Puts Valuation And Adoption In Focus

Intuit (NasdaqGS:INTU) has announced a major AI partnership with Anthropic to build custom AI agents and integrated financial tools. The collaboration is aimed at mid market businesses and consumers, with Intuit’s financial data and tooling woven into Anthropic’s products. The partnership focuses on compliant, secure AI solutions that can be surfaced across multiple platforms and workflows. For you as an investor, this move sits at the intersection of Intuit’s core strengths in tax,...
NYSE:CFR
NYSE:CFRBanks

Assessing Cullen/Frost Bankers (CFR) Valuation As Recent Trading Sends Mixed Short Term Signals

Cullen/Frost Bankers (CFR) has drawn fresh attention after recent trading, with the share price closing at $140.21 and posting mixed short term returns while still showing gains over the past 3 months and year. See our latest analysis for Cullen/Frost Bankers. The recent 1 day share price return of 1.44% sits against a 7 day share price return of negative 1.35%. At the same time, the 90 day share price return of 13.93% and 1 year total shareholder return of 7.14% point to momentum that has...
NasdaqGM:APGE
NasdaqGM:APGEBiotechs

Apogee’s Deeper Losses and New Shelf Filing Test Its High-Risk Pipeline Strategy (APGE)

Apogee Therapeutics reported a full-year net loss of US$255.84 million for 2025, with basic and diluted loss per share of US$4.22 as it continued to report no product revenue while investing heavily in its antibody pipeline. Alongside deeper losses, the company underscored upcoming clinical milestones for zumilokibart and other programs and filed a US$287.29 million shelf registration tied to an employee stock ownership plan, highlighting both capital needs and efforts to align employee...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Is Astera Labs (ALAB) Quietly Building a Moat in AI Data Center Connectivity Infrastructure?

Astera Labs has recently deepened its AI data center role by acquiring aiXscale Photonics, expanding with an Israel Design Center, and advancing its vendor‑neutral connectivity solutions through UALink participation and hyperscaler partnerships. This expansion into optical interconnects and closer collaboration with major cloud providers could reinforce Astera Labs’ position as a key infrastructure enabler in next‑generation AI data centers. We’ll now examine how the aiXscale Photonics...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

A Look At ImmunityBio (IBRX) Valuation After ANKTIVA Trial Progress And New Regulatory Milestones

ImmunityBio (IBRX) is back in focus after completing enrollment ahead of schedule in its Phase 2 ANKTIVA bladder cancer trial. Interim data show statistically significant response durability compared with BCG alone and no significant safety concerns. See our latest analysis for ImmunityBio. The latest ANKTIVA trial update arrives after a significant 3-month share price return of about 3.7x and a 416.83% year-to-date share price return, alongside a 245.70% 1-year total shareholder return. This...
NYSE:HCA
NYSE:HCAHealthcare

HCA Board Shift As Robert Dennis Retires And Governance Priorities Evolve

HCA Healthcare director Robert J. Dennis plans to retire from the board at the upcoming annual meeting. He will not stand for re election, which will reduce the current slate of directors following the meeting. The transition focuses attention on HCA Healthcare’s board composition and future oversight of the business. For investors watching NYSE:HCA, this board change comes at a time when the company’s shares are trading around $532.92. The stock has seen a 13.3% return year to date and a...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Clover Health’s Counterpart Platform Puts Technology Model In Sharper Focus

Clover Health Investments (NasdaqGS:CLOV) reports very large year over year growth in third party clinician adoption of its Counterpart Health platform. The technology is now used widely outside the company’s own plans, with third party adoption described as more than 4.5x higher year over year. Counterpart Health has achieved a top HEDIS score nationally for a PPO Medicare Advantage plan with a non employed physician network. Clover Health Investments, listed on NasdaqGS:CLOV, runs...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

Assessing Axon Enterprise (AXON) Valuation After Strong Results And 2026 Growth Guidance

Why Axon’s latest results caught investor attention Axon Enterprise (AXON) drew fresh interest after releasing fourth quarter and full year 2025 results, showing higher revenue alongside much lower net income, and pairing that with new 2026 guidance that calls for 27% to 30% revenue growth. See our latest analysis for Axon Enterprise. The earnings release and 2026 guidance arrived alongside a sharp short term move, with a 35.1% 7 day share price return and a 5.5% 1 day gain. The 3 year total...
NYSE:MCO
NYSE:MCOCapital Markets

Moody's (MCO) Is Up 6.6% After Strong Q4 2025 Results And New Riyadh Hub Opening

Moody’s Corporation recently reported higher fourth-quarter and full-year 2025 results, continued its share repurchase program, filed a shelf registration for new debt securities, and earlier in February opened a new regional headquarters in Riyadh to deepen its presence in Saudi Arabia and the wider Middle East. Together, stronger earnings and the Riyadh regional hub highlight how Moody’s is pairing profit growth with a broader international footprint in a key capital‑markets region. We’ll...